Study of AZD0292 in Chinese patients with bronchiectasis and chronic Pseudomonas infection
Part of Infections, Lungs & breathing clinical trials.
This study tests a new medication called AZD0292 for people with bronchiectasis who have a long-term Pseudomonas infection. It aims to see if the drug can reduce flare-ups and improve lung health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and weigh at least 35 kg (about 77 lbs).
- You have bronchiectasis confirmed by a CT scan (within the last 5 years).
- You have had at least 2 moderate or 1 severe flare-up in the past year, needing antibiotics.
- You have had a Pseudomonas infection in your lungs in the last 2 years.
- You have not had a flare-up in the last 4 weeks and are otherwise stable.
- You do not need long-term oxygen therapy (oxygen with exercise is okay).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug given through an IV to see if it can reduce lung infections and flare-ups in people with bronchiectasis who have a chronic pseudomonas infection. Participation may help improve symptoms and quality of life.
This trial tests a new drug called CTX-187 in two groups: healthy volunteers (Parts A and B) and people with chronic lung infection from bronchiectasis (Part C). It helps find the right dose and checks safety.
This trial tests whether a new medication, BI 1291583, can help people with bronchiectasis reduce lung infections and symptoms. You may join if you have had at least one or two lung flare-ups in the past year.
This trial tests two different antibiotic treatments for adults with bronchiectasis who have a new or recent infection with Pseudomonas aeruginosa (PA) bacteria in their airways. The goal is to see which regimen works better to clear the infection early.
This trial tests a new drug called AZD6793 for people with moderate to very severe COPD. It aims to see if the drug can help improve breathing and reduce flare-ups.
This trial tests if a new drug, GSK3862995B, is safe and effective for adults with bronchiectasis. It might help reduce lung infections and improve symptoms.
Hear when a new Bronchiectasis With Pseudomonas Aeruginosa Colonization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.